A summary of the efficacy of ublituximab (briumvi) on prevention of relapses and MRI activity in multiple sclerosis (data from the ULTIMATE I/II trials) pmc.ncbi.nlm.nih.gov/articles/PMC...
October 21, 2025 at 4:10 AM
A summary of the efficacy of ublituximab (briumvi) on prevention of relapses and MRI activity in multiple sclerosis (data from the ULTIMATE I/II trials) pmc.ncbi.nlm.nih.gov/articles/PMC...
Awesome! I'm starting Briumvi tomorrow.
January 7, 2025 at 3:21 PM
Awesome! I'm starting Briumvi tomorrow.
YES it costs that much. For Briumvi. Just a SINGULAR vial costs $11,870 (150 mg/6 mL) and for a year $59,000 (6 vials ≈ 3 infusions)
July 8, 2025 at 1:25 AM
YES it costs that much. For Briumvi. Just a SINGULAR vial costs $11,870 (150 mg/6 mL) and for a year $59,000 (6 vials ≈ 3 infusions)
#TGTX TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
https://www.stocktitan.net/news/TGTX/tg-therapeutics-announces-data-presentations-for-briumvi-in-multiple-o7zjmc3v0cko.html
https://www.stocktitan.net/news/TGTX/tg-therapeutics-announces-data-presentations-for-briumvi-in-multiple-o7zjmc3v0cko.html
New Clinical Data Reveals BRIUMVI's Impressive Safety Profile in Multiple Sclerosis Treatment
Latest real-world and clinical studies demonstrate BRIUMVI's safety in MS patients, including 30-minute infusion tolerability data. See complete findings.
www.stocktitan.net
May 30, 2025 at 11:30 AM
#TGTX TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
https://www.stocktitan.net/news/TGTX/tg-therapeutics-announces-data-presentations-for-briumvi-in-multiple-o7zjmc3v0cko.html
https://www.stocktitan.net/news/TGTX/tg-therapeutics-announces-data-presentations-for-briumvi-in-multiple-o7zjmc3v0cko.html
Neutropenia (low neutrophils, a type of white blood cell) is a rare side effect of b-cell depleting drugs (ocrevus, rituximab, briumvi, kesimpta) and occurs "at a rate of 0.66 per 100 person-years" and can cause infections. (from @UCSF) pubmed.ncbi.nlm.nih.gov/40537081/
Neutropenia Associated With B Cell-Depleting Therapies in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder - PubMed
This study is comprehensive and reflects a large cohort, examining incidence rates of neutropenia with BCDT in MS and NMOSD. Overall, neutropenia was still rare, occurring at a rate of 0.66 per 100 pe...
pubmed.ncbi.nlm.nih.gov
June 20, 2025 at 5:20 AM
Neutropenia (low neutrophils, a type of white blood cell) is a rare side effect of b-cell depleting drugs (ocrevus, rituximab, briumvi, kesimpta) and occurs "at a rate of 0.66 per 100 person-years" and can cause infections. (from @UCSF) pubmed.ncbi.nlm.nih.gov/40537081/
Briumvi for Multiple Sclerosis Explained by Neurologist
patienttalk.org/briumvi-for-...
patienttalk.org/briumvi-for-...
January 21, 2025 at 12:54 PM
Briumvi for Multiple Sclerosis Explained by Neurologist
patienttalk.org/briumvi-for-...
patienttalk.org/briumvi-for-...
Just saw a commercial for an MS drug called Briumvi. If you don't know how to pronounce it, just sing it to the tune of "Taaaake oooooon meeeee." Because that's what they did in the ad.
Can't we just go back to "O, O, O, Ozempic"?
Can't we just go back to "O, O, O, Ozempic"?
May 31, 2025 at 12:57 AM
Just saw a commercial for an MS drug called Briumvi. If you don't know how to pronounce it, just sing it to the tune of "Taaaake oooooon meeeee." Because that's what they did in the ad.
Can't we just go back to "O, O, O, Ozempic"?
Can't we just go back to "O, O, O, Ozempic"?
United Healthcare has been refusing to pay for Briumvi for 6 months now. Their excuses are now down to "we couldn't read the nurse's handwriting."
I miss being able to yell at them on Twitter, trash company that they are.
I miss being able to yell at them on Twitter, trash company that they are.
November 15, 2023 at 7:10 PM
United Healthcare has been refusing to pay for Briumvi for 6 months now. Their excuses are now down to "we couldn't read the nurse's handwriting."
I miss being able to yell at them on Twitter, trash company that they are.
I miss being able to yell at them on Twitter, trash company that they are.
Can you deescalate from a b-cell depleting drug (i.e. ocrevus, briumvi, rituximab, kesimpta) to tecfidera? This study (n=648) found those switching to tecfidera had lower rates of relapses and a lower rate of hospitalization due to infection. pubmed.ncbi.nlm.nih.gov/39936542/
Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims database - PubMed
<span><b>Aim:</b> Anti-CD20 monoclonal antibodies and fumarates are common multiple sclerosis (MS) disease-modifying therapies (DMTs). Data on switching from anti-CD20s to other DMTs are limited. This...
pubmed.ncbi.nlm.nih.gov
February 13, 2025 at 4:32 AM
Can you deescalate from a b-cell depleting drug (i.e. ocrevus, briumvi, rituximab, kesimpta) to tecfidera? This study (n=648) found those switching to tecfidera had lower rates of relapses and a lower rate of hospitalization due to infection. pubmed.ncbi.nlm.nih.gov/39936542/
This document provides a detailed overview of emerging treatments for multiple sclerosis (MS).
The field is moving toward personalized medicine with biomarker-driven treatment selection, CNS-penetrant therapies, and high-efficacy-first approaches to slow progression.
docs.google.com/document/d/e...
The field is moving toward personalized medicine with biomarker-driven treatment selection, CNS-penetrant therapies, and high-efficacy-first approaches to slow progression.
docs.google.com/document/d/e...
June 12, 2025 at 7:50 PM
This document provides a detailed overview of emerging treatments for multiple sclerosis (MS).
The field is moving toward personalized medicine with biomarker-driven treatment selection, CNS-penetrant therapies, and high-efficacy-first approaches to slow progression.
docs.google.com/document/d/e...
The field is moving toward personalized medicine with biomarker-driven treatment selection, CNS-penetrant therapies, and high-efficacy-first approaches to slow progression.
docs.google.com/document/d/e...
It's #Briumvi day and my infusion has begun 90 minutes late. It's going to be a day, I can tell. #MultipleSclerosis
October 16, 2024 at 4:47 PM
It's #Briumvi day and my infusion has begun 90 minutes late. It's going to be a day, I can tell. #MultipleSclerosis
All DMTs for MS are insanely expensive.
The CD20 meds per year:
• Briumvi - $69k
• Kesimpta - $129k
• Ocrevus - $68k
• Rituximab - $30k to $50k (off-label use; costs vary widely)
The CD20 meds per year:
• Briumvi - $69k
• Kesimpta - $129k
• Ocrevus - $68k
• Rituximab - $30k to $50k (off-label use; costs vary widely)
January 13, 2025 at 2:00 AM
All DMTs for MS are insanely expensive.
The CD20 meds per year:
• Briumvi - $69k
• Kesimpta - $129k
• Ocrevus - $68k
• Rituximab - $30k to $50k (off-label use; costs vary widely)
The CD20 meds per year:
• Briumvi - $69k
• Kesimpta - $129k
• Ocrevus - $68k
• Rituximab - $30k to $50k (off-label use; costs vary widely)
TG Therapeutics wants to develop a subcutaneous (under-the-skin) version of Briumvi analagous to ocrevus zunovo multiplesclerosisnewstoday.com/news-posts/2...
TG developing under-the-skin version of MS therapy Briumvi
TG Therapeutics said it is working to develop a subcutaneous (under-the-skin) version of relapsing MS therapy Briumvi.
multiplesclerosisnewstoday.com
January 19, 2025 at 7:30 AM
TG Therapeutics wants to develop a subcutaneous (under-the-skin) version of Briumvi analagous to ocrevus zunovo multiplesclerosisnewstoday.com/news-posts/2...
Neuraxpharm's Strategic Launch in Australia to Enhance Global CNS Treatment Access#Australia#Sydney#Neuraxpharm#CNS#BRIUMVI
Neuraxpharm's Strategic Launch in Australia to Enhance Global CNS Treatment Access
Neuraxpharm continues its global expansion by launching Neuraxpharm Australia, focusing on CNS treatments like BRIUMVI and Nuvigil.
third-news.com
July 22, 2025 at 12:04 AM
Neuraxpharm's Strategic Launch in Australia to Enhance Global CNS Treatment Access#Australia#Sydney#Neuraxpharm#CNS#BRIUMVI
Risk factors for serious infections while taking b-cell depleting multiple sclerosis drugs (ocrevus, rituximab, kesimpta, briumvi): Low IgG (antibody) levels. Taking it for a long time. Having a greater level of existing disability. pubmed.ncbi.nlm.nih.gov/39835156/
January 21, 2025 at 8:53 PM
Risk factors for serious infections while taking b-cell depleting multiple sclerosis drugs (ocrevus, rituximab, kesimpta, briumvi): Low IgG (antibody) levels. Taking it for a long time. Having a greater level of existing disability. pubmed.ncbi.nlm.nih.gov/39835156/
#TGTX TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
https://www.stocktitan.net/news/TGTX/tg-therapeutics-reports-second-quarter-2025-financial-results-and-gk27yackstrn.html
https://www.stocktitan.net/news/TGTX/tg-therapeutics-reports-second-quarter-2025-financial-results-and-gk27yackstrn.html
TG Therapeutics Smashes Earnings: BRIUMVI Sales Surge 91%, Company Lifts 2025 Revenue Target
Q2 revenue hits $141.1M as MS drug BRIUMVI leads growth. Company raises full-year guidance to $575M and achieves profitability. See detailed results.
www.stocktitan.net
August 4, 2025 at 11:00 AM
#TGTX TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
https://www.stocktitan.net/news/TGTX/tg-therapeutics-reports-second-quarter-2025-financial-results-and-gk27yackstrn.html
https://www.stocktitan.net/news/TGTX/tg-therapeutics-reports-second-quarter-2025-financial-results-and-gk27yackstrn.html
Non-interventional, prospective, multicenter study to evaluate treatment satisfaction, treatment preference, quality of life, and tolerability under treatment with Briumvi® for relapsing forms of multiple sclerosis (RMS) with active disease in daily clinical practice
#MSchat #Neurology #MultipleScl
#MSchat #Neurology #MultipleScl
July 1, 2024 at 7:07 PM
lol suits my bear personality too, the fatigue is the worst. The optic neuritis permanently damaged my optic nerves so the central vision is lacking contrast 100% of the time. i live on dark mode as it minimizes washing out details.
hope the Briumvi works well ʕ•ᴥ•ʔ
hope the Briumvi works well ʕ•ᴥ•ʔ
a bear laying on its back next to a tree with its mouth open
ALT: a bear laying on its back next to a tree with its mouth open
media.tenor.com
September 18, 2025 at 5:09 PM
lol suits my bear personality too, the fatigue is the worst. The optic neuritis permanently damaged my optic nerves so the central vision is lacking contrast 100% of the time. i live on dark mode as it minimizes washing out details.
hope the Briumvi works well ʕ•ᴥ•ʔ
hope the Briumvi works well ʕ•ᴥ•ʔ
I originally wanted Kesimpta, but got “lol no” and they handed me Briumvi instead. Honestly? Not mad. One hour every 6 months, and all I get is a runny nose for a few weeks and my B-cells packing their shit. No fridge-stabbing. Would I switch? Only if Kesimpta comes with better snacks.
#ByeBCells
#ByeBCells
May 21, 2025 at 11:18 PM
I originally wanted Kesimpta, but got “lol no” and they handed me Briumvi instead. Honestly? Not mad. One hour every 6 months, and all I get is a runny nose for a few weeks and my B-cells packing their shit. No fridge-stabbing. Would I switch? Only if Kesimpta comes with better snacks.
#ByeBCells
#ByeBCells
#TGTX TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
https://www.stocktitan.net/news/TGTX/tg-therapeutics-announces-schedule-of-data-presentations-for-briumvi-nkijitxc4br5.html
https://www.stocktitan.net/news/TGTX/tg-therapeutics-announces-schedule-of-data-presentations-for-briumvi-nkijitxc4br5.html
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
TG Therapeutics (NASDAQ: TGTX) has announced upcoming presentations featuring BRIUMVI® (ublituximab-xiiy) data at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting in Phoenix, Arizona from May 28-31, 2025. The presentations include three key studies: 1. A platform presentation on the relationship between serum immunoglobulin levels and infections during long-term ublituximab treatment by Dr. Bruce Cree 2. A poster on infusion tolerability from the ENAMOR real-world observational survey presented by Dr. Edward Fox 3. A poster updating safety and tolerability data of 30-minute ublituximab infusions from the ENHANCE study by Dr. John Foley All presentations are scheduled for May 29, 2025, and the data will be made available on TG Therapeutics' website after the presentations.
www.stocktitan.net
May 27, 2025 at 11:30 AM
#TGTX TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
https://www.stocktitan.net/news/TGTX/tg-therapeutics-announces-schedule-of-data-presentations-for-briumvi-nkijitxc4br5.html
https://www.stocktitan.net/news/TGTX/tg-therapeutics-announces-schedule-of-data-presentations-for-briumvi-nkijitxc4br5.html
All done for 6 months. Solu-medrol, benadryl, Briumvi, and bonus dexamethasone for a few days. My legs feel strong and my symptoms are fading. #MultipleSclerosis
April 3, 2025 at 8:03 PM
All done for 6 months. Solu-medrol, benadryl, Briumvi, and bonus dexamethasone for a few days. My legs feel strong and my symptoms are fading. #MultipleSclerosis
Here's where we are today. United Healthcare has refused to pay for my initial Briumvi treatment that took place on May 23, 2023. In six days it will be one year without payment. 1/?
#UnitedHealthcare #UHC #Briumvi #MultipleSclerosis
#UnitedHealthcare #UHC #Briumvi #MultipleSclerosis
May 17, 2024 at 8:55 PM
Here's where we are today. United Healthcare has refused to pay for my initial Briumvi treatment that took place on May 23, 2023. In six days it will be one year without payment. 1/?
#UnitedHealthcare #UHC #Briumvi #MultipleSclerosis
#UnitedHealthcare #UHC #Briumvi #MultipleSclerosis
Briumvi for sure has a crap gap. Month 6 is a bitch and getting worse. #MultipleSclerosis #MS
October 24, 2023 at 8:53 PM
Briumvi for sure has a crap gap. Month 6 is a bitch and getting worse. #MultipleSclerosis #MS
My last Briumvi was April 1st. Yesterday my neuro told me UHC rejected the claim. Again. As they do every single treatment.
It's only been 3 months. If you recall UHC took 13 months to pay for my first Briumvi treatment.
It's only been 3 months. If you recall UHC took 13 months to pay for my first Briumvi treatment.
July 23, 2025 at 11:17 AM
My last Briumvi was April 1st. Yesterday my neuro told me UHC rejected the claim. Again. As they do every single treatment.
It's only been 3 months. If you recall UHC took 13 months to pay for my first Briumvi treatment.
It's only been 3 months. If you recall UHC took 13 months to pay for my first Briumvi treatment.